Humacyte Raises $20 Million in Direct Offering and Lands Saudi Symvess Purchase Pact

Overview

• Humacyte priced a registered direct sale of 25,000,000 common shares for expected gross proceeds of $20 million, with closing targeted on or about March 20, 2026.
• A new life-science–focused investor and a long-only mutual fund led the financing, and Titan Partners is serving as sole placement agent.
• The company said proceeds will support U.S. commercialization of Symvess for vascular trauma, a planned hemodialysis BLA supplement, an upcoming Phase 3 read-out, pipeline projects, and working capital.
• Humacyte disclosed a minimum $1.475 million commitment to purchase Symvess for a clinical evaluation and outreach program in Saudi hospitals, with Humacyte providing clinician training and negotiating KSA commercialization rights exclusively through July 2, 2026.
• Symvess holds FDA approval for urgent arterial repair after extremity vascular trauma, and a separate report said Humacyte submitted a Marketing Authorization Application in Israel on March 17, 2026.